Curida has come a long way from defending their place at the Norwegian factory to setting their sights internationally. What is Curida and their goal all about?
Creating value within ones own country while steadily spreading roots globally is no easy feat, but the young Norwegian pharmaceutical company Curida is blooming.
Overcoming the threat at Elverum
The company’s history is a classic tragedy intertwined with devotion and a feel-good ending. In 2013, change of ownership and new strategic priorities threatened to strip 190 employees from their jobs at the manufacturing site in Elverum, Norway. New owners Takeda announced that the site in Elverum was to be shut down, after providing pharmaceutical manufacturing since 1974.
What followed was a feat of patience and outstanding motivation. Employees and management joined forces to establish a new company, form a new business model, and get going. In July 2015, Curida was established and operation carried on.
Oslo Cancer Cluster member Curida is now a Contract Development and Manufacturing Organization, offering expertise in manufacturing and development of liquid pharmaceuticals.
The Curida customer base ranged from early-phase biotech companies to large, multinational pharma companies. Further growth in the international market is a top priority for the company. Curida is specialized on liquid products, using for example the advanced blow-fill-seal technology.
Naturally, Curida has ambitious goals for home as well.
– In Norway we work closely with other start-up companies and make sure to help them thrive in production and innovation. Regardless of our vision to be a top-competitor internationally, locally, in Norway, we strive to become a national centre for industrialisation of medical innovation, says CEO Leif Rune Skymoen.
After overcoming the potential reality of shutting down, Curida now bursts through with unstoppable energy and ambition.